Cargando…

Cardiovascular and pharmacological implications of haem-deficient NO-unresponsive soluble guanylate cyclase knock-in mice

Oxidative stress, a central mediator of cardiovascular disease, results in loss of the prosthetic haem group of soluble guanylate cyclase (sGC), preventing its activation by nitric oxide (NO). Here we introduce Apo-sGC mice expressing haem-free sGC. Apo-sGC mice are viable and develop hypertension....

Descripción completa

Detalles Bibliográficos
Autores principales: Thoonen, Robrecht, Cauwels, Anje, Decaluwe, Kelly, Geschka, Sandra, Tainsh, Robert E., Delanghe, Joris, Hochepied, Tino, De Cauwer, Lode, Rogge, Elke, Voet, Sofie, Sips, Patrick, Karas, Richard H., Bloch, Kenneth D., Vuylsteke, Marnik, Stasch, Johannes-Peter, Van de Voorde, Johan, Buys, Emmanuel S., Brouckaert, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4699393/
https://www.ncbi.nlm.nih.gov/pubmed/26442659
http://dx.doi.org/10.1038/ncomms9482
Descripción
Sumario:Oxidative stress, a central mediator of cardiovascular disease, results in loss of the prosthetic haem group of soluble guanylate cyclase (sGC), preventing its activation by nitric oxide (NO). Here we introduce Apo-sGC mice expressing haem-free sGC. Apo-sGC mice are viable and develop hypertension. The haemodynamic effects of NO are abolished, but those of the sGC activator cinaciguat are enhanced in apo-sGC mice, suggesting that the effects of NO on smooth muscle relaxation, blood pressure regulation and inhibition of platelet aggregation require sGC activation by NO. Tumour necrosis factor (TNF)-induced hypotension and mortality are preserved in apo-sGC mice, indicating that pathways other than sGC signalling mediate the cardiovascular collapse in shock. Apo-sGC mice allow for differentiation between sGC-dependent and -independent NO effects and between haem-dependent and -independent sGC effects. Apo-sGC mice represent a unique experimental platform to study the in vivo consequences of sGC oxidation and the therapeutic potential of sGC activators.